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A B S T R A C T
Introduction: Bisphosphonate treatment in adults with hypophosphatasia (HPP) may increase fracture risk. PLP
is a useful marker in biochemically differentiating HPP from osteoporosis in adults. In order to identify elevated
PLP, robust reference intervals are needed which are calculated in a large, representative sample population.
Methods: Complete data from 9069 individuals (ages 2080, 50.6% female) from two years of the NHANES
Survey (20072008 and 20092010) were investigated. Differences in PLP in the presence of four factors; in-
flammation (CRP ≥5.0 mg/L), low ALP (< 36 IU/L), chronic kidney disease (eGFR<60 mL/min/1.732), and
daily vitamin B6 supplementation, were investigated. Race, gender and age differences in PLP were then in-
vestigated; 95% reference intervals were calculated that reflected these differences.
Results: Inflammation and chronic kidney disease were associated with lower PLP (p < .0001 and p = .0005
respectively), while low ALP and vitamin B6 supplementation were associated with higher PLP (both
p < .0001). Individuals were excluded based on the presence of these factors; a reference interval population
(n = 4463) was established. There were significant differences in PLP depending on race and gender
(p < .0001) Increasing age was correlated with decreasing PLP (spearman's rho −0.204, p < .0001). Race-
and gender-specific 95% reference intervals were calculated. In male patients, these were also calculated ac-
cording to age groups: young and older adults (ages 2049 years and ≥50 years respectively).
Conclusions: In order to identify adult hypophosphatasia based on elevated PLP, considerations must be made
depending on the race, gender and age of the individual. Factors associated with significant differences in PLP
must also be considered when assessing biochemical measurements.
1. Introduction
Hypophosphatasia (HPP) is a rare genetic disorder characterised by
mutations of the tissue non-specific alkaline phosphatase (TNSALP)
gene. There is a high heterogeneity in the clinical presentation of HPP,
with complications mainly originating from the skeleton. Adults with
HPP typically present in middle age and their signs and symptoms in-
clude recurrent non-healing stress fractures (typically of the meta-
tarsals), history of early shedding of deciduous teeth, thigh pain which
can indicate femoral pseudofractures, chondrocalcinosis, osteoarthro-
pathy and muscle weakness [1,2].
TNSALP is expressed in the skeleton, liver and kidney. Its main
natural substrates are inorganic pyrophosphate (PPi), pyridoxal 5
phosphate (PLP) and phosphoethanolamine (PEA). The bone-specific
isoform of alkaline phosphatase (ALP) is required for the normal
mineralisation of bone and the development of teeth. In HPP, the lack
of the TNSALP activity is expressed by accumulation of PPi, a potent
inhibitor of mineralisation [3].
Due to the wide range and severity of HPP symptoms and the low
prevalence of the disease, diagnosis of adult HPP may prove difficult
and it is often overlooked. Patients with fractures can be mistaken for
having osteoporosis, a more common disease. Bisphosphonates, which
are analogues of pyrophosphate, are the main drugs used in the treat-
ment of osteoporosis. However, there have been several studies which
suggest that treatment with bisphosphonate in HPP patients may result
in atypical, usually non-traumatic subtrochanteric and femoral shaft
fractures [46]. Therefore, it is critical to be able to suspect and diag-
nose HPP accurately.
The biochemical findings of HPP are persistently low serum ALP
levels [2]. An inverse relationship has been described between
https://doi.org/10.1016/j.bone.2020.115577
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circulating PLP levels and ALP. Patients with hepatic diseases and
malignancy have been found to have reduced PLP levels [79]. On the
contrary, patients with HPP have been found to have elevated PLP le-
vels and its measurement has been described as a more sensitive and
specific marker than a low ALP level for diagnosing HPP [2,9]. PLP is
the biologically active and most abundant form of vitamin B6
(7090%), a term that refers to six interconvertible compounds: pyr-
idoxine (PN), pyridoxamine (PM), and pyridoxal (PL), and their phos-
phorylated derivatives pyridoxine 5-phosphate (PNP), pyridoxamine 5-
phosphate (PMP), and pyridoxal 5-phosphate (PLP) [10,11]. PLP as-
sessment has some challenges, as PLP decreases in samples stored at
room temperature due to dephosphorylation to PL. It has been pre-
viously recommended that when sample handling is not optional,
summarising the results of PLP as B6-aldehyde (PLP + PL) should be
performed but this has not been validated. PLP is light sensitive so it is
recommended that serum/plasma sample handling is carried out under
non-UV lighting. [1113]. It can decrease after high carbohydrate in-
take so it is best to obtain fasting samples. PLP is bound to albumin and
several factors can affect its level like alcohol consumption, albumin
concentration, smoking, inflammation and drugs (antiepileptics, non-
steroidal anti-inflammatory drugs, hydralazine, isoniazid etc.) [11].
In order to reliably utilise PLP as a marker of HPP, robust PLP re-
ference intervals are needed to reflect the population-based differences
in PLP. Currently reported reference intervals for PLP show poor
agreement, possibly as a result of the unrepresentative populations
from which they are derived. There is an indication from collected la-
boratory reported 95% reference intervals (RIs) that gender differences
exist in PLP levels [14].
Factors which may be associated with significant differences in PLP
should be identified and excluded where present from the reference
interval population. A previous investigation using data from the
20052006 National Health and Nutrition Examination Survey showed
significant differences in PLP based on the presence of inflammation
(defined as C-reactive protein, CRP ≥5.0 mg/L), but no difference in
PLP in individuals with chronic kidney disease (CKD) stage 35 [de-
fined as estimated glomerular filtration rate (eGFR)<60 mL/min/
1.732] when compared to participants with normal kidney function
(eGFR ≥60 mL/min/1.73 m2 and absence of albuminuria) [15]. These
findings need to be confirmed. Moreover, other factors like the asso-
ciation between low ALP levels and the levels of PLP have to be in-
vestigated. PLP is elevated in response to high dietary vitamin B6 in-
take, so associations between the daily supplement intake and
differences in circulatory PLP should also be studied.
We used a combined dataset encompassing the 20072008 and
20092010 NHANES collections to investigate the associated differ-
ences in PLP in the presence of four factors of interest: inflammation,
chronic kidney disease, low ALP, and vitamin B6 supplement intake
[16].
The aims of our study were:
1. To examine factors associated with significant differences in PLP in
a representative United States (US) population sample.
2. To test for the presence of race, gender and age differences in PLP
3. To calculate 95% RIs for PLP that reflect these differences.
2. Materials and methods
2.1. Study population
All study data was drawn from The National Health and Nutrition
Examination Survey (NHANES). NHANES is an annual, cross-sectional
collection of health and nutritional data in the general, non-in-
stitutionalised US population. Data from 20,015 subjects collected
during two years of the survey were collated (20072008, n = 9762,
20092010, n = 10,253).
This study only included data from adults (ages 2080) from three
pre-defined race/ethnicity groups, Hispanic-Mexican American, Non-
Hispanic Black and Non-Hispanic White. Cases with ambiguous race/
ethnicity identification (Hispanic-Other Hispanic, Other) were excluded
based on the difficulty of applying the Modification of Diet in Renal
Disease Study (MDRD) equation which requires the specification of race
to calculate eGFR [17]. Cases were omitted where data was incomplete
for any variable of interest. Prior to examination of potential con-
founders of PLP, we did not exclude any subjects on the basis of any
health conditions in order to best represent the general population.
Overall, the total study population was n = 9069. Young adults were
defined as 2049 years old, and older adults ages 50 and older.
Further exclusions were made based on the presence of one or more
known confounders of PLP (inflammation, chronic kidney disease, low
ALP, and vitamin B6 supplement intake irrespective of the dose of vi-
tamin B6), providing a final reference interval population of n = 4463.
2.2. Biochemical measurements
All biochemical measurements were completed as part of the
NHANES programme.
The 20072008 and 20092010 datasets were selected as both years
included measurement of serum PLP by the same reversed-phase high
performance liquid chromatography (HPLC) method with post-column
derivatisation and fluorometric detection. This is the method used in
everyday practice to measure PLP [18,19]. The laboratory procedure
manual used by NHANES recommended fasting samples, shipped on
dry ice by an overnight carrier and then stored at −70 °C. If re-
frigerated samples were sent, they were only used if delivered within
2 h of collection [13].
The estimated glomerular filtration rate was calculated from serum
creatinine [15] using the MDRD equation [17]. Chronic kidney disease
(CKD) stage 35 was defined as eGFR<60 mL/min/1.732 [20].
Inflammation was defined as CRP ≥5.0 mg/L, while low ALP
as< 36 IU/L [15].
2.3. Statistical analyses
Statistical analyses were performed using MedCalc version 16.8.4
(MedCalc Software, Ostend, Belgium) and R studio statistical software,
version 1.1.442 (RStudio, Inc., Boston, Massachusetts).
PLP values for the whole population were not normally distributed
and so non-parametric tests were used. The Mann-Whitney U test was
used to identify differences in PLP in the presence and absence of the
four variables of interest.
A multiple linear regression was performed to first explore whether
gender, race and age had an effect on PLP levels. Later, the Mann-
Whitney U test was used to check for gender and age group differences
in PLP. Differences in PLP associated with race were assessed using the
Kruskal-Wallis test. A correlation analysis using Spearman's rho was
also used for age. Parametric tests (student's t-test and analysis of var-
iance) were used to compare differences in daily dietary B6.
For the alcohol consumption analysis, we have used the following
definition for higher alcohol consumption: ≥12 units in women and
≥14 units in men. Smokers were defined as the participants who re-
sponded to the question Do you now smoke cigarettes with either
everyday or some days. The Mann-Whitney U test was used to
check for differences in PLP in smokers vs non-smokers and participants
with higher alcohol consumption vs the rest. A multiple linear regres-
sion was then performed to explore whether gender had an interaction
between alcohol or smoking. The explanatory variables used were
gender, smoking, alcohol and the interaction between gender and al-
cohol and gender and smoking. For all tests significance was defined as
p < .05.
For the calculation of reference intervals, the relevant function on
MedCalc was used, following using a non-parametrical percentile
method as described by the Clinical and Laboratory Standards Institute
M. Schini, et al. %RQH

(CLSI). Reed's criterion was used to look for outliers [21].
3. Results
The general characteristics of the study population before and fol-
lowing exclusions are presented in Table 1. Overall, the total study
population was 9069 (50.6% female; n = 4458 from 2007 to 2008;
n = 4611 from 2009 to 2010). Further exclusions were made based on
the presence of one or more known confounders of PLP [inflammation
(n = 2108); chronic kidney disease (n = 741); low ALP (n = 199);
vitamin B6 supplementation (n = 2633)], providing a final reference
interval population of n= 4463, 44.4% female (n= 2188 from 2007 to
2008; n = 2275 from 2009 to 2010). The mean intake of vitamin B6 in
diet in the reference population was 2.0 mg (SD 1.3).
3.1. Confounder analysis
All four tested variables were associated with significant differences
in PLP (Table 2). PLP was significantly lower in individuals with in-
flammation (p < .0001), and those with chronic kidney disease
(p = .0005). Conversely PLP was shown to be significantly higher in
subjects with low ALP (p < .0001), and those receiving a vitamin B6
supplement (p < .0001).
3.2. Gender, race and age differences in PLP
In the multiple linear regression model, age, gender and race were
independent predictors of PLP levels (all p values< .0001). Gender and
race differences in PLP were found in the reference interval population
(Table 3). Female patients and black race had lower levels. There was a
gradual decrease of PLP associated with increasing age [Spearman's rho
−0.204 (95% confidence intervals −0.232; −0.176), p < .0001].
When testing for differences between the two age groups (young and
old adults), a significant difference was found (the young adults had
higher PLP levels, p < .0001). However, when testing for differences
in age groups within females and males, young males had significantly
higher PLP values than old males (p < .001), whereas female parti-
cipants had similar PLP values independent of their age group
(p = .136) (Table 3).
A further analysis was performed to check whether the differences
in PLP could be explained by different dietary intake of vitamin B6.
Male participants had a higher mean consumption of dietary vitamin B6
(2.3 and 1.7 mg respectively, p < .001). Young participants had a
higher consumption when compared to older ones (2.1 and 1.9 re-
spectively, p < .001). The difference remained significant when
comparing younger and older males (p < .001) and females (p 0.018).
There was no difference in the amount of dietary vitamin B6 according
to race (p 0.654).
3.3. Smoking and alcohol consumption
Smokers had lower levels of PLP than non-smokers [median (in-
terquartile range) in nmol/L: 32.1 (20.8; 51.3), 39.2 (25.9; 58.1) re-
spectively, p < .0001]. PLP did not differ between participants with
higher alcohol consumption compared to the rest (p = .210). The
multiple linear regression showed no interaction of gender with
smoking or alcohol [variables studied: gender (p = .002), alcohol
(p= .595), smoking (p= .609), gender-alcohol interaction (p= .367),
gender-smoking interaction (p 0.739)].
3.4. 95% reference intervals
Due to the differences in PLP relative to gender, race and age (in
Table 1
Baseline population characteristics before exclusions (total population) and
after exclusions to establish the reference interval population.
Populations Total population
(n = 9069)
Reference interval population
(n = 4463)
Female (%) 50.6 44.4
Age (years)a 50 (36 to 65) 45 (32 to 60)
PLP (nmol/L)a 42.9 (25.4 to 74.9) 38.6 (25.3 to 58.8)
CRP (mg/L)a 2.0 (0.8 to 4.7) 1.4 (0.6 to 2.6)
eGFR (mL/min/1.732)a 92.8 (77.1 to 110.0) 97.9 (83.5 to 114.3)
ALP (IU/L)a 67 (54 to 81) 66 (54 to 79)
Race categories; n (%):
Mexican American 1892 (20.9) 1129 (25.3)
Non-Hispanic White 5220 (57.5) 2345 (52.4)
Non-Hispanic Black 1957 (21.6) 989 (22.2)
a Data are presented in median (interquartile range). PLP: pyridoxal 5
phosphate.
Table 2
Pyridoxal 5 phosphate (PLP) in subjects according to the presence and absence
of tested confounders.
PLP (nmol/L),
median (IQR)
Sig.
Inflammation (CRP ≥5.0 mg/L) No
n = 6961
47.4 (28.7 to 82.8) p < .0001
Yes
n = 2108
29.3 (18.3 to 52.6)
CKD (eGFR<60 mL/min/1.732) No
n = 8328
43.2 (25.8 to 75.0) p = .0005
Yes
n = 741
37.5 (21.4 to 74.2)
Low ALP (< 36 IU/L) No
n = 8870
42.4 (25.1 to 73.5) p < .0001
Yes
n = 199
83.3 (50.0 to
137.5)
Vitamin B6 supplementation No
n = 6436
34.5 (22.2 to 55.1) p < .0001
Yes
n = 2633
81.3 (48.2 to
143.0)
CRP: C-reactive protein; CKD: chronic kidney disease; eGFR: estimated glo-
merular filtration rate; ALP: alkaline phosphatase; IQR: interquartile range.
Table 3
Comparison of gender and race differences in pyridoxal 5 phosphate (PLP) in
the reference interval population (n = 4463).
PLP (nmol/L), median
(IQR)
Sig.
Gendera Male (n = 2483) 43.3 (28.7 to 64.9) p < .0001
Female (n = 1980) 33.2 (22.4 to 51.6)
Race/ethnicityb Mexican Americanc
(n = 1129)
44.6 (30.0 to 63.9) p < .0001
Non-Hispanic Whitec
(n = 2345)
37.8 (24.6 to 58.1)
Non-Hispanic Blackc
(n = 989)
34.3 (22.8 to 55.0)
Agea Young (n = 2641) 42.4 (28.0 to 63.6) p < .0001
Old (n = 1822) 33.3 (22.0 to 52.6)
Age and gender Young male
(n = 1439)
50.4 (34.3 to 72.6) p < .0001
Old male
(n = 1044)
34.2 (22.7 to 53.8)
Young female
(n = 1202)
33.6 (23.0 to 51.8) p = .136
Old female
(n = 778)
32.3 (21.3 to 51.3)
a Mann-Whitney U Test was used for gender and age group comparisons.
b Kruskal Wallis Test was used for race comparisons.
c Post-hoc analysis showed each race was significantly different from the two
other races (p < .05). Young: age < 50 years; old: age ≥ 50 years; IQR:
interquartile range.
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males), the 95% RIs were stratified to reflect these differences (Table 4).
4. Discussion
The standardised protocol of NHANES allowed us to combine data
from two years of the programme, providing an increased sample re-
presentative of the general US population. PLP was found to be higher
in males than in females and different across all race/ethnicity groups
(highest in Mexican Americans). In males, there was a significant dif-
ference between young and older adults. Due to this large sample we
have been able to calculate robust 95% reference intervals for PLP. To
the best of our knowledge this is the first report of gender-, race-, and
age-specific 95% reference intervals of PLP where proven confounders
of PLP have been excluded from the study population.
We have observed a lot of variation around the upper limit of the
reference intervals; black women have the lowest upper limit
(92.7 nmol/L) compared to black men who have the highest
(170.0 nmol/L). The differences in the upper limit of the RIs show the
importance of gender/race/age stratification for the diagnosis of HPP.
The decrease of PLP with age has been described in study of men
who were not taking vitamin B6 supplements [22]. It was also de-
scribed in a previous study using NHANES data from 2003 to 2004. As
this decrease could be theoretically explained by poor intake or changes
caused by illness in older participants, the researchers controlled for
diet, diabetes, creatinine, smoking, and alcohol intake and excluded
participants with renal dysfunction, heart attack or stroke history.
Possible explanations for this finding have been suggested to be de-
creased absorption, accelerated catabolism, and decreased phosphor-
ylation of B6 [23]. In this study, amongst participants not on B6 sup-
plements, PLP decreased significantly with increasing age in males after
controlling for creatinine; with male teens having the highest plasma
PLP levels. Female participants, both using and not using B6 supple-
ments, had lower PLP levels than males, however, there was a pattern
to this gender-difference. Differences started in menarche, with teen
girls having similar levels of PLP to teen boys before, and differences
disappearing again as more women progressed to menopause. This
pattern suggests an association between the levels of estrogen and PLP
[23]. It has been previously reported that oral contraceptive (OC) use
can decrease PLP, but the mechanism is not well-understood. Possible
explanations include the redistribution of PLP in the tissues, the in-
duction of PLP-dependent enzymes involved in the tryptophan pathway
by the use of OC, increasing the need for vitamin B6 and increased CRP
caused by the use of OC [24]. However, the decreased PLP levels in
females, are not completely explained by estrogen use, with both
teenage girls and adult women never on OC use, having significantly
lower PLP levels than similar-aged men [23]. We have found higher
dietary consumption of vitamin B6 in males and younger participants.
This could explain the differences by gender and age in PLP. Another
explanation of the higher levels of PLP in men, is that levels increase
with alcohol consumption and cigarette smoking, habits more common
in men [25]. Once these are adjusted for, there is no longer any gender
difference [25]. However, in previous studies, current smokers were
found to have lower PLP levels compared to non-smokers [23,26]. We
also found an effect of lifestyle on PLP levels, with smokers having
lower PLP levels than non-smokers. However, we did not find an in-
teraction between smoking or alcohol consumption with gender.
We found differences in PLP levels in the different races included in
the data. Lower PLP levels in non-Hispanic blacks compared with non-
Hispanic whites were previously reported [23]. These differences could
not be explained by differences in dietary vitamin B6.
Of the four tested physiological variables (inflammation, chronic
kidney disease, low ALP and vitamin B6 supplement intake), all were
associated with significant differences in PLP compared to individuals
without these factors. PLP was lower in people with inflammation de-
fined by high CRP; this effect has been shown previously [27,28], in-
cluding an investigation of data from the 20052006 NHANES database
[15]. Most of the serum PLP (approximately 90%) is albumin bound
[9]; during periods of inflammation increased capillary permeability
leads to movement of plasma albumin into the extravascular space,
while pro-inflammatory cytokines suppress hepatic production of al-
bumin, leading to reduced serum levels of PLP [27].
Chronic kidney disease was associated with lower PLP in our study.
This does not align with a previous investigation that reported no dif-
ference in PLP between NHANES participants with normal kidney
function (eGFR≥60 mL/min/1.73 m2 and absence of albuminuria) and
those with stage 35 CKD (eGFR<60 mL/min/1.732). However a third
group was included in that analysis (CKD stage 1 or 2, defined as eGFR
≥60 mL/min/1.73 m2 and presence of albuminuria) [15] which was
not represented in our study, as our investigation did not evaluate the
presence of albuminuria and only included two groups (normal kidney
function and CKD stage 35).
PLP was higher in individuals with low ALP (< 36 IU/L), than those
with normal or high values. This negative correlation has been pre-
viously documented [29]. Higher PLP in cases of low ALP may be a
result of inadvertent identification of HPP within the population, thus
PLP is higher in these individuals.
PLP was also higher in individuals taking vitamin B6 supple-
mentation, compared with those who were not. This was reported be-
fore, using data from the NHANES study 20032004; PLP increased by
about 12 nmol/L per 1 mg increase in vitamin B6 intake [23]. There-
fore, blood tests in clinical investigation of PLP should be taken at least
a few weeks after the cessation of supplementary vitamin B6 intake
although the exact timing is not clear from the literature [3034].
The strengths of this study include the use of a large sample re-
presentative of the non-institutionalised US population. The major
limitation of this analysis relates to the cross-sectional design of the
Table 4
Race and gender-specific 95% reference intervals (RI) for pyridoxal 5 phosphate (PLP) in adults.
Race/ethnicity Age group PLP (nmol/L), median (95% RI) 90% CI of lower limit 90% CI of upper limit
Male
Mexican American Young, n = 389 54.8 (21.8 to 170.5) 18.0 to 26.9 147.0 to 237.0
Old, n = 216 39.0 (15.8 to 146.8) 12.1 to 16.6 131.0 to 178.0
Non-Hispanic White Young, n = 737 48.1 (16.7 to 180.0) 14.8 to 18.0 149.0 to 210.0
Old, n = 595 34.3 (11.0 to 195.1) 9.7 to 12.0 138.0 to 222.0
Non-Hispanic Black Young, n = 313 46.9 (16.0 to 220.3) 13.5 to 18.8 170.0 to 278.0
Old, n = 233 30.0 (9.1 to 131.2) 8.2 to 10.8 108.0 to 277.0
Female
Mexican American All, n = 524 36.7 (13.0 to 167.3) 12.0 to 14.0 138.0 to 242.0
Non-Hispanic White All, n = 1013 32.2 (10.8 to 176.7) 9.6 to 11.6 141.0 to 219.0
Non-Hispanic Black All, n = 443 29.5 (9.0 to 110.5) 8.0 to 10.1 92.7 to 130.0
In male participants, the results are presented according to two different age groups: young (< 50 years) and old (≥50 years). In female participants, PLP levels did
not differ between the two age groups so the reference interval is given for the whole population. CI: confidence interval.
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NHANES programme. This prohibits exploration of cause and effect
relationships between PLP and other biomarkers. Blood samples are
collected only once from each participant and so fluctuations in bio-
markers over time cannot be understood. This is relevant in the inter-
pretation of low ALP which may be transiently low in a range of sce-
narios without an effect on PLP levels, whereas persistently low ALP is
often suggestive of HPP. The presence of albuminuria was not studied
when evaluating the effect of kidney function. Dietary sources and in-
take of vitamin B6 was not considered for this study in order to reflect
normal dietary differences in the population. Differences in dietary
intake of vitamin B6 could provide insight into the observed differences
in PLP.
In conclusion, four factors (inflammation, chronic kidney disease,
low ALP and vitamin B6 supplement intake), have been shown to be
associated with differences in PLP and should be considered in the in-
terpretation of clinical PLP measurements. We have reported PLP
gender-, race-, and age-specific 95% reference intervals for use in ev-
eryday clinical practice.
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Summary
In order for serum pyridoxal 5-phosphate (PLP) to be used as a
marker of hypophosphatasia (HPP) in adults, robust reference intervals
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gender and age differences in PLP in a representative US population and
calculated PLP reference intervals that reflect these differences. Factors
proven to be associated with significant differences in PLP were ex-
cluded from the population.
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